

Edith A. Nutescu

Curriculum Vitae

BUSINESS ADDRESS:

The University of Illinois at Chicago
College of Pharmacy (M/C 886)
Department of Pharmacy Practice
833 S. Wood St; MC 886; Room 164
Chicago, Illinois 60612
Phone: (312) 996-0880
Pager: (312) 996-2242 #4948
Fax: (312) 413-4805
E-mail: enutescu @ uic.edu

EDUCATION / POST - GRADUATE TRAINING:

1996 Certification in Anticoagulation
ASHP Research and Education Foundation
Anticoagulation Service Traineeship
Veterans Affairs Medical Center
Buffalo, New York

1995 - 1996 Primary Care Specialty Residency - ASHP Accredited
University of Illinois at Chicago Medical Center
College of Pharmacy
Chicago, Illinois

1994 - 1995 Pharmacy Practice Residency - ASHP Accredited
Lutheran General Hospital/Advocate Health Care
Park Ridge, Illinois

1990 - 1994 Doctor of Pharmacy, graduated with high-honors
University of Illinois at Chicago
College of Pharmacy
Chicago, Illinois

1989 - 1990 Pre-Pharmacy Curriculum
Wilbur Wright College
Chicago, Illinois

1983 - 1988 Bachelor of Science - Chemical Engineering
Politechnical Institute of Bucharest
Bucharest, Romania

LICENSURE: Registered Pharmacist, Illinois # 051-039827

ACADEMIC APPOINTMENTS:

2004 - Present
Clinical Associate Professor
Department of Pharmacy Practice
University of Illinois at Chicago
College of Pharmacy
Chicago, Illinois

1996 - 2004
Clinical Assistant Professor
Department of Pharmacy Practice
University of Illinois at Chicago
College of Pharmacy
Chicago, Illinois

PROFESSIONAL EXPERIENCE:

2000 – Present
Assistant Director
Ambulatory Care Pharmacy: Nutrition and Wellness Center
University of Illinois at Chicago
Chicago, Illinois

1996 - Present
Director
Antithrombosis Center
University of Illinois at Chicago Medical Center
Chicago, Illinois

1996 - Present
Pharmacotherapist
Ambulatory Care & Nutrition and Wellness Center
Services covered: Stroke Risk Reduction - Hyperlipidemia,
Antithrombosis, Medication Management
University of Illinois at Chicago Medical Center
Chicago, Illinois

1994 - 1997
Registered Pharmacist
Lutheran General Hospital/Advocate Health Care
Park Ridge, Illinois

1992 - 1994
Pharmacy Extern
St. Joseph Hospital
Chicago, Illinois

1991 - 1993
Research Assistant
University of Illinois at Chicago Medical Center
Department of Urology
Chicago, Illinois

TEACHING ACTIVITIES:

Didactic Teaching:

PHAR 402/405: Principles of Drug Action and Therapeutics
Lecturer and Recitation Leader; Second year Pharm.D. students
Topic: “Oral Anticoagulants”
University of Illinois at Chicago, College of Pharmacy
Fall Semester 1999 - 2005

PHAR 352: Experiential II
Lecturer; Second year Pharm.D. students
Topic: Physical Assessment of the Peripheral Vascular System
University of Illinois at Chicago, College of Pharmacy
Fall Semester 1998 - 2005

DADM 341: Dental Therapeutics
Lecturer; Fourth year D.D.S students
Topic: Anticoagulation in dental surgery patients
University of Illinois at Chicago, College of Dentistry
Summer 1998 - 2000; Fall Semester 2000 – 2004

PHAR 324: Contemporary Pharmacy Practice
Lecturer and Recitation Leader; Third year Pharm.D. students
Topic: “Home Diagnostic Products.”
University of Illinois at Chicago, College of Pharmacy
Spring Semester 1999 - 2005

PHAR 653/PMPR 651: Pharmacotherapeutics I
Section Coordinator and Lecturer; CCO students
Topic: Hemostasis and Thrombosis
University of Illinois at Chicago, College of Pharmacy
Fall Semester 1997 - 2000; Spring Semester 2001 - 2003

NUMS 532/533: Pharmacotherapeutics for Advanced Practice Nursing
Lecturer; Nurse Practitioner students
Topic: Hemostasis and Thrombosis; Antithrombotic Therapy
University of Illinois at Chicago, College of Nursing
Fall Semester 2001 - 2005

PHAR 346: Pharmacy Services and Reimbursement
Lecturer; Third year PharmD students
Topic: Getting Reimbursed for Clinical Pharmacy Services
University of Illinois at Chicago, College of Pharmacy
Spring Semester 2000 - 2001

PHAR 343: Pharmacy Systems Management
Lecturer; Second year Pharm.D. students

Topic: How to Establish A New Pharmacy Service
University of Illinois at Chicago, College of Pharmacy
Spring Semester 1999 - 2000

PMPR 375/385: Careers in Pharmacy.
Course Coordinator; First year Pharm.D. students
University of Illinois at Chicago, College of Pharmacy
Spring Semester 1998 - 2000

PMPR 371: Advanced Therapeutics - Ambulatory Care I
Course Coordinator; Third year Pharm.D. students
University of Illinois at Chicago, College of Pharmacy
Fall Semester 1997 - 1998

PHAR 341: Roles, Environments, Communications
Service Learning Portfolio Project
Coordinator; First year Pharm.D. students
University of Illinois at Chicago, College of Pharmacy
Fall Semester 1997, Spring Semester 1998

PMPR 380/390: Special Projects in Pharmacy Practice
Coordinator; First – Third year Pharm.D students
University of Illinois at Chicago, College of Pharmacy
Fall and Spring Semesters: 1997 – 2005

PMPR 371: Advanced Therapeutics - Ambulatory Care I
Lecturer; Third year Pharm.D. students
Topics: Drug Related Problems; Thyroid Disorders; Anticoagulation
University of Illinois at Chicago, College of Pharmacy
Fall Semester 1997 - 1998

PMPR 373: Advanced Therapeutics - Hospital Practice I
Lecturer; Third year Pharm.D. students
Topic: Clinical Laboratory Monitoring
University of Illinois at Chicago, College of Pharmacy
Fall Semester 1997 - 1998

PMPC 304: Dosage Form Design. Pharmaceutics IV.
Lecturer and Lab facilitator; Third year Pharm.D. students
Topic: “Home Diagnostic Products.”
University of Illinois at Chicago, College of Pharmacy.
Fall Semester 1996 - 1998

PMPC 304: Dosage Form Design. Pharmaceutics IV.
Facilitator; Third year Pharm.D. students
Topic: “Simulated patient interviews and counseling.”
University of Illinois at Chicago, College of Pharmacy.
Fall 1996

PMPR 350: Ambulatory Care Clerkship Conference.

Discussion Leader; Fourth year Pharm.D. students.
University of Illinois at Chicago, College of Pharmacy.
Topics: “Hypertension”, “Anticoagulation.”
1995 – 1999

PMPR 371: Ambulatory Care Elective.
Facilitator; Third year Pharm.D. students.
University of Illinois at Chicago, College of Pharmacy.
Topics: “Patient Education”, “Community Pharmacy”, “Asthma”, “Lipids”, “Contraception,”
“Congestive Heart Failure,” “Ischemic Heart Disease.”
Fall Semester 1995 - 1996

PMPC 304: Dosage Form Design. Pharmaceutics IV.
Facilitator; Third year Pharm.D. students.
University of Illinois at Chicago, College of Pharmacy.
Topics: “Cough and Cold Products.”
Fall Semester 1995

Experiential Teaching:

PMPR 384: Advanced Ambulatory Care Clerkship
Preceptor; Fourth year Pharm.D. students.
University of Illinois at Chicago, Wellness Center & Antithrombosis Clinic.
2005

PHAR 371/660: Ambulatory Care Clerkship
Preceptor; Fourth year Pharm.D. students.
University of Illinois at Chicago, Wellness Center & Antithrombosis Clinic.
1996 - 2005

Ambulatory Care Rotation
Preceptor; Pharmacy Practice Residents, Primary Care Specialty
Residents, and Community Practice Resident.
University of Illinois at Chicago, Wellness Center & Antithrombosis Clinic.
1996 - 2005

PHAR 354: Experiential IV
Preceptor; Third year Pharm.D. students
University of Illinois at Chicago, College of Pharmacy
Fall Semester 1999 - 2005

PMPR 346: Clinical Skills
Preceptor; Fourth year Pharm.D. students
University of Illinois at Chicago, Antithrombosis Clinic
Fall Semester 1997

“Dominick’s” Pharmacy Experiential Program
Preceptor; Practicing pharmacists.

University of Illinois at Chicago, Antithrombosis Clinic.
1997 - 1998

Singapore General Hospital, Singapore – Collaborative Program
Preceptor; Visiting Scholars
The University of Illinois at Chicago, Antithrombosis Clinic
1998-2005

Meiji College of Pharmacy, Tokyo, Japan - Collaborative Program
Preceptor; Visiting Scholars
The University of Illinois at Chicago, Antithrombosis Clinic
1997 – 1998

International Collaborative Programs: Hong Kong, Thailand, China, England, India, Australia,
Singapore.
Preceptor; Visiting Scholars, Undergraduate and Graduate Students, Residents
The University of Illinois at Chicago, Antithrombosis Clinic
1998 – 2005

Post-Doctoral Fellows and Residents Mentored:

Beth Duplaga, Pharm.D; Ambulatory Care Resident. University of Illinois at Chicago. 1999-2000.

Christina Rivers, Pharm.D; Ambulatory Care Resident. University of Illinois at Chicago. 2000-2001.

Simon Lee, Pharm.D; Ambulatory Care Resident. University of Illinois at Chicago. 2000-2001.

Juan Blackburn, MD; Pharmacoeconomics Research Fellow (research emphasis in antithrombotic therapy). University of Illinois at Chicago. 2003-2005.

PUBLICATIONS:

Articles in Refereed Journals:

Nutescu EA, Park HY, Walton SM, Blackburn JC, Finley JM, Lewis RK, Schumock GT. Factors that influence prescribing within a therapeutic class. *J Eval Clin Prac* 2005;11(4):357-65.

Nutescu EA, Helgason CM. Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis. *Curr Treat Options Cardiovasc Med* 2005;7(3):241-50.

Nutescu EA, Wittkowsky AK, Dager WE. Uncertain times for oral anticoagulation therapy. *Am J Health Syst Pharm* 2005;62(14):1449.

Spinler SA, Wittkowsky AK, Nutescu EA, Smythe MA. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin. *Ann Pharmacother* 2005; 39(7-8):1275-85.

Spinler SA, Nutescu EA, Smythe MA, Wittkowsky AK. Anticoagulation monitoring part 1: Warfarin and parenteral direct thrombin inhibitors. *Ann Pharmacother* 2005;39(6):1049-55.

Nutescu EA, Shapiro NL, Chevalier A, Amin AN. A pharmacologic overview of current and emerging anticoagulants. *Cleve Clin J Med* 2005;72(Suppl1):S2-6.

Wittkowsky AK, Sekreta CM, Nutescu EA, Ansell J. Barriers to patient self-testing of prothrombin time: national survey of anticoagulation practitioners. *Pharmacotherapy* 2005;25(2):265-9.

Haines ST, Nutescu EA. Current and emerging treatment options for venous thrombosis: a case discussion. *Am J Health Syst Pharm* 2005;62(6):593-605.

Nutescu EA. Point of care monitors for oral anticoagulant therapy. *Semin Thromb Hemost* 2004;30(6):697-702.

Bongiorno RA, Nutescu EA. Generic warfarin: implications for clinical practice and perceptions of anticoagulation providers. *Semin Thromb Hemost* 2004;30(6):619-26.

Nutescu EA, Spinler SA, Dager WE, Bussey HI. Transitioning from traditional to novel anticoagulants: the impact of oral direct thrombin inhibitors on anticoagulation management. *Pharmacotherapy* 2004;24(10 Pt 2):199S-202S.

Nutescu EA. Emerging options in the treatment of venous thromboembolism. *Am J Health Syst Pharm* 2004;61(23 Suppl 7):S12-17.

Nutescu EA. Strategies for cost-effective prevention and treatment of venous thromboembolism. Introduction. *Am J Health Syst Pharm* 2004;61(23 Suppl 7):S3-4.

Nutescu EA, Helgason CM, Briller J, Schwertz DW. New Blood Thinner Offers First Potential alternative in 50 Years: Ximelagatran. *J Cardiovasc Nurs*. 2004;19(6):374-383.

Dager WE, Vondracek TG, McIntosh BA, Nutescu EA. Ximelagatarn: an oral direct thrombin inhibitor. *Ann Pharmacother* 2004;38(11):1881-97.

Nutescu EA, Pickard SA, Blackburn JC, Wittkowsky AK, Ansell J, Schumock GT. Impact of Oral Direct Thrombin Inhibitors on Anticoagulation Clinics. *Pharmacotherapy* 2004;24(9):1204-1212.

Nutescu EA, Bauman JL. Shifting paradigms in oral anticoagulation management. *J Cardiovasc Pharamacol Ther*. 2004;3:149-50.

Schumock GT, Blackburn JC, Nutescu EA, Walton SM, Finley JM, Lewis RK. Impact of prescribing guidelines for inpatient anticoagulation. *Ann Pharmacother* 2004;38(10):1570-5.

- Nutescu E, Singh-Khalsa M. Treatment of Venous Thromboembolism: Challenging the Unfractionated Heparin Standard. *Pharmacotherapy* 2004;24(8 Pt 2):127S-131S.
- Helgason CM, Anthu Do M, Nutescu E. Warfarin in Patients with Stroke and Reasons for Discontinuation. *J Stroke Cerebrovas Dis* 2004;13(2):70-73.
- Dager WE, Andersen J, Nutescu EA. Special Considerations with Fondaparinux Therapy: Heparin-Induced Thrombocytopenia and Wound Healing. *Pharmacotherapy* 2004;24(7 Pt 2):88S-94S.
- Nutescu EA, Helgason CM. Evolving Concepts in the Treatment of Venous Thromboembolism: The Role of Factor Xa Inhibitors. *Pharmacotherapy* 2004;24(7 Pt 2):82S-87S.
- Nutescu EA. Current Concepts in Thrombosis Management: Focus on Factor Xa Inhibition. *Pharmacotherapy* 2004;24(7 Pt 2):61S.
- Wittkowsky AK, Whitely KS, Devine EB, Nutescu EA. Effect of age on international normalized ratio at the time of major bleeding in patients treated with warfarin. *Pharmacotherapy* 2004;24(5):600-5.
- Schumock GT, Walton SM, Park HY, Nutescu EA, Blackburn JC, Finley JM, Lewis RK. Factors that influence prescribing decisions. *Ann Pharmacother* 2004;38(4):557-62.
- Nutescu EA, Wittkowsky AK Direct thrombin inhibitors for anticoagulation. *Ann Pharmacother* 2004;38(1):99-109.
- Nutescu EA, Shapiro NL, Feinstein H, Rivers CW. Tinzaparin: considerations for use in clinical practice. *Ann Pharmacother* 2003;37(12):1831-40.
- Nutescu EA. The future of anticoagulation clinics. *J Thromb Thrombolysis* 2003;16(1-2):61-3.
- Nutescu EA. Antithrombotic therapy for the treatment of venous thromboembolism. *Am J Manag Care* 2003;9(5S):103-114.
- Nutescu EA, Shapiro NL. Ezetimibe: a selective cholesterol absorption inhibitor. *Pharmacotherapy* 2003;23(11):1463-74.
- Peters PC, Nutescu E, Andersen J. Wound pharmacobiology. *Orthopedics* 2003;26(8S):837-842.
- Nutescu EA, Lewis RK, Finley JM, Schumock GT. Hospital guidelines for use of low-molecular-weight heparins. *Ann Pharmacother* 2003;37:1072-81.
- Schumock GT, Nutescu E, Walton SM, Arondekar B, Lewis RK. Survey of hospital policies regarding low-molecular-weight heparins. *Am J Health-Syst Pharm* 2002;59:534-538.
- Nutescu E, Racine E. Traditional versus modern anticoagulant strategies: Summary of the literature. *Am J Health-System Pharm* 2002; 59(S6):s7-s14.

Duplaga B, Rivers C, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. *Pharmacotherapy* 2001;21(2):218-234.

Shek KLA, Chan LN, Nutescu E. Warfarin-acetaminophen drug interaction revisited. *Pharmacotherapy* 1999;19(10):1153-8.

Nutescu E, Hunt C, Teeters JL. Multidisciplinary approach to improving allergy documentation. *Am J Health-Syst Pharm* 1998;55:364-8.

Articles in Non-Refereed Journals:

Nutescu EA, Spyropoulos AC, Cranmer KW. Oral anticoagulation: preparing for change. *J Am Med Dir Assoc*. 2004;5(5):2-10.

Nutescu EA. Clinical Applications of Novel Anticoagulants in High-Risk Patient Populations: Obesity, Renal Insufficiency, and Pregnancy. *Frontiers in HematOncology*. 2004;Summer edition: 4-6.

Nutescu EA. Anticoagulation Therapy in Managed Care. *Anticoagulation Digest* 2004;1(1):1,5,6.

Lyons RM, Andersen JC, Frame DG, Franklin R, Houlihan N, Nutescu EA, Vance-Stark V. Clinical Symposia Reports: Evidence-Based Review of Tinzaparin Sodium and Guidelines for Administration. *Clinical Advances in Hematology & Oncology* 2003;Dec:1-11.

Nutescu EA. Treatment of venous thromboembolism: Emerging trends in anticoagulation. *Pharmacy Times* 2003:Sept:37-44. (ACPE Accredited)

Fraser M, Nutescu E, Jacobs LG. Anticoagulation in long-term care: state of the art. *J Am Med Dir Assoc*. 2002;3(4):H17-20.

Nutescu EA. Antithrombotic therapy for the prevention of venous thromboembolism. *US Pharmacist* 2002;27(11):HS65-HS76. (ACPE Accredited)

Nutescu E. Novel antithrombotic agents for the prevention of venous thromboembolism. ACPE Special Report. *Pharmacy Practice News* 2001;Nov:1-8.

Shek KLA, Gedey RJ, Nutescu E. Homocysteine and atherosclerotic vascular disease. *KeePosted* 1999; 24(6):10-14.

Nutescu E, Pubentz M. Outpatient treatment for DVT: New opportunities for Anticoagulation Clinics. *Forum Facts* 1999; Spring:II(1):1-4,10.

Nutescu E. Low molecular weight heparins: A focus on outpatient use. *KeePosted* 1998; 23(10):6-16. (ACPE Accredited)

Nutescu E. Oral anticoagulation therapy for pulmonary thromboembolism. *KeePosted* 1997; 22(1) 8-10.

Hunt C, Nutescu E. Assessing and preventing drug induced allergy. *KeePosted* 1995;20(8):7-12.

Nutescu E. Interpreting blood cultures. *KeePosted* 1995;20(4):7-8.

Nutescu E. Stavudine: A new antiretroviral agent. *KeePosted* 1994;19(8):6-7.

Published Abstracts:

Blackburn J, Schumock G, Nutescu EA, Walton SM, Finley JM, Lewis R. Impact of Prescribing Guidelines for Inpatient Anticoagulation. International Society for Pharmacoeconomics and Outcomes Research, 10th Annual International Meeting. Washington, DC, May 15-18, 2005.

Blackburn J, Walton SM, Nutescu EA, Park H, Schumock G, Lewis R, Finley JM. Factor that Influence Prescribing of Low-Molecular-Weight Heparins. International Society for Pharmacoeconomics and Outcomes Research, 10th Annual International Meeting. Washington, DC, May 15-18, 2005.

King KM, Wong C, Nutescu EA, Shord Shifflett S. Warfarin dose requirements in cancer and non-cancer patients. American College of Clinical Pharmacy, Spring Practice and Research Forum. Myrtle Beach, SC, April 11, 2005. Abstract published in: *Pharmacotherapy* 2005;25(3):468. Abstract # 107.

Momary KM, Fashingbauer LA, Shapiro NL, Nutescu EA, Helgason CM, Pandey DK, Cavallari LH. Demographic and environmental influences of warfarin response in African Americans. American College of Clinical Pharmacy, Annual Meeting. Dallas, TX, October 26, 2004. Abstract published in: *Pharmacotherapy* 2004;24(10):1423. Abstract # 23.

Nutescu EA, Pickard AS, Blackburn JC, Wittkowsky AK, Ansell J, Schumock GT. Implications of Oral Direct Thrombin Inhibitors for Anticoagulation Clinics. The 2nd ACCP-ESCP International Congress on Clinical Pharmacy. Paris, France, April 28 – 29, 2004.

Humma L, Helgason CM, Zhong E, Shapiro N, Young L, Nutescu EA. Glycoprotein IIIa genotype and aspirin response in stroke. American Stroke Association, 29th International Stroke Conference. San Diego, CA, February 2004. Abstract Published in: *Stroke* 2004;35(1):235. Abstract #3.

Blackburn JC, Park HY, Nutescu EA, Walton SM, Finley JM, Lewis RK, Schumock GT. Factors that influence prescribing decisions. *Value in Health* 2004;7(3):372-373. Abstract PHP 20.

Nutescu E, Sullivan SD, Davidson BL. Fondaparinux is cost-effective compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing surgery for hip fracture: a trial-based analysis. American Society of Health-System Pharmacists, Midyear Clinical Meeting. New Orleans, LA, December 2003. Abstract published in: *International Pharmaceutical Abstracts* 2003; 38(Dec): p P-344(E).

Nutescu EA, Park HY, Walton SM, Lewis RK, Finley JM, Blackburn JC, Schumock GT. “Factors that influence the prescribing of low-molecular-weight heparins in community hospitals: opinions of physicians, clinical pharmacists, and formulary committee members.” *J Thromb Haemost* 2003; Supplement 1 (July 1): P1854.

Whitely K, Wittkowsky A, Devine B, Nutescu EA. The association between age and INR in patients with warfarin-related major bleeding complications. *Pharmacotherapy* 2003;23(10):1342. Abstract # 97.

Nutescu EA, Humma LM, Fashingbauer LA, Pham CM, Helgason CM. “Factors influencing the activity of antiplatelet agents in stroke patients.” *Pharmacotherapy* 2002;22(3):406.

Butler MG, Nutescu EA, Finley JM, Lewis RK, Schumock GT. “Guidelines for use of low-molecular-weight heparins in acute care hospitals.” American Society of Health-System Pharmacists, Midyear Clinical Meeting. Atlanta, GA, December 2002. Abstract published in: *International Pharmaceutical Abstracts* 2002; 37(Dec): p P-484D.

Helgason CM, Nutescu EA, Taber R, Brace LD. “Concurrent thrombophilia in patients with ischemic stroke.” *Thromb Hemost* 2001;July (Suppl 1): P2182

Lee S, Shapiro N, Nutescu EA. “Outpatient low molecular weight heparin bridge therapy in patients receiving oral anticoagulation.” *Journal of Thrombosis and Thrombolysis* 2001;12:109.

Arondekar BV, Nutescu EA, Walton SW, Lewis RK, Schumock GT. “Policies for use of low molecular weight heparins.” *ASHP Midyear Clinical Meeting* 2001; 36(Dec): p P-307E.

Nutescu EA, Helgason C. “Outpatient Dalteparin peri-procedure bridge therapy in patients maintained on long term warfarin.” *Stroke* 2001;32:328e-9e.

Engle JP, Shapiro NL, Nutescu EA, Maloney M. “Using NetPodium as a tool to deliver content in an online antithrombosis certificate program.” *AACP Annual Meeting* 2001;102(Jul):p102.

Nutescu EA, Lewis R, Engle J. “Developing an online anticoagulation clinic certificate program.” *Journal of Thrombosis And Thrombolysis* 2000;9(Suppl 1):S69.

Nutescu EA, Helgason CM. “Combination aspirin-clopidogrel therapy in patients with ischemic stroke: the representation of interaction.” *Stroke* 2000; 31(1): 6.

Engle J, Nutescu E, Shapiro N. “Using the internet to deliver an online anticoagulation clinic certificate program.” *AACP Annual Meeting* 2000;101(Jul):p178.

Bongiorno R, Nutescu EA. “A national survey of anticoagulation clinics on the use of brand versus generic warfarin.” *Pharmacotherapy* 1999;19(10):1204.

Mitchell J, Wong M, Nutescu EA. “Comparison of outcomes for antithrombosis clinic patients managed in the clinic versus over the telephone.” *Pharmacotherapy* 1999;19(4):528.

Shek A, Nutescu EA, Shapiro N, Volkman J, Lewis R, Helgason CM. “Expanding services in a pharmacist-managed stroke-antithrombosis clinic to include hyperlipidemia management.” *Pharmacotherapy* 1999;19(4):519.

Nutescu EA, Jahng J, Lewis R. “Justification and mechanisms of revenue generation in a pharmacist-managed antithrombosis clinic.” *Pharmacotherapy* 1999;19(4):508.

Lewis R, Nutescu EA. “The utilization of prescription revenue to assist in the cost justification of pharmacist-managed clinics.” *Pharmacotherapy* 1999;19(4):508.

Nutescu E, Helgason CM. “Warfarin-aspirin combination therapy: patient outcomes in a stroke antithrombosis clinic.” *Stroke* 1999;30(1):258.

Sanoski CA, Takahashi H, Echizen H, Brace L, Helgason C, Schuler J, Bauman JL, Nutescu E. “Effect of cigarette smoking on the pharmacokinetics of warfarin.” *Pharmacotherapy* 1998; 18(5):1142.

Sanoski CA, Takahashi H, Echizen H, Brace L, Helgason C, Schuler J, Bauman JL, Nutescu E. “Effect of gender on the pharmacokinetics of warfarin.” *Pharmacotherapy* 1998;18(2) 427.

Sanoski CA, Takahashi H, Echizen H, Brace L, Helgason C, Schuler J, Bauman JL, Nutescu E. “Effects of age and weight on the pharmacokinetics of warfarin.” *Pharmacotherapy* 1998;18(2):427.

Lundquist NR, Nutescu E, Lewis RK. “Integration of a clinical pharmacy technician in a pharmacist-managed antithrombosis clinic.” *ASHP Midyear Clinical Meeting* 1998;33(Dec):p TECH-17.

Engle JP, Nutescu E, Joseph J. “Developing an anticoagulation clinic certificate program.” *AACP Annual Meeting* 1998;99(Jul):p83.

Nutescu E, Hoffman M, Wilken L, Straube D, Mobley-Smith M. “Integrating an interdisciplinary service-learning model in the pharmacy curriculum.” *AACP Annual Meeting* 1998;99(Jul):p109.

Teeters JL, Nutescu EA, Hunt C. “Multidisciplinary approach to improving allergy documentation.” *International Pharmaceutical Abstracts* 1996; 33(9):787.

Nutescu EA, Teeters JL. “Accuracy of documenting drug allergies.” *International Pharmaceutical Abstracts* 1995;32(9):777.

Nutescu EA, Harris E. “Ifosfamide induced pancreatitis.” *International Pharmaceutical Abstracts* 1995;32(9):794.

Nutescu EA, Teeters JL, Peterson CW. “Documenting pharmacist interventions.” *International Pharmaceutical Abstracts* 1994;31(21):2325.

Other Creative Work/Meeting Proceedings/Monographs/Journal Supplements/Newsletters:

Nutescu EA. “Antithrombotic Therapy Considerations in Special Patient Populations “ A Continuing Education (CME) Web-Based Expert Commentary found on: www.ThrombosisClinic.com. Sponsored and produced by Elsevier Science, Continuing Education, Hillsborough, NJ. April 2005.

Nutescu EA, Smythe MA. “Anticoagulants: Clinical and Practical Considerations.” A Continuing Education (ACPE) Audioconference Series, sponsored by the American Academy of CME, Inc. and Interactive Network for Continuing Education, Cranbury, NJ. March 14, 2005 – March 15, 2006.

Nutescu EA, (Co-Editor), Koeller JM. *Frontiers in HematOncology*. 2004;Summer:1-11. ACPE Accredited Newsletter. Published by BioScience Communications, New York, NY.

Nutescu EA, Spyropoulos AC, Cranmer KW. “Oral Anticoagulation: Preparing for Change.” Proceedings of a live symposium held at the American Medical Directors, Annual Meeting; 2004 March 5; Phoenix, AZ. CME Accredited. Sponsored by The University of Texas Health Sciences Center at San Antonio Medical School; Published in association with the American Medical Directors Association.

Nutescu EA. Consultant Editor: *Anticoagulation Digest*, 2004. A series of 6 ACPE accredited newsletters. Published by Princeton Media Associates, LLC, Millstone Township, NJ.

Nutescu EA. Advances in Thromboprophylaxis for Hip Replacement Surgery. *The Monthly Prescribing Reference DVT Management Guide* 2004 Edition:p9-28. Published by Prescribing Reference, Inc. New York, NY.

Nutescu EA, (Program Chair), Hanson P, Kaatz S, Wittkowsky AK, Vermeulen LC. “New Directions in Thrombosis Management: Adopting Optimal Treatment Strategies.” Proceedings and CD-Rom of a live symposium held at the American Society of Health-Systems Pharmacists, Midyear Clinical Meeting; 2004 December 5; Orlando, FL. ACPE Accredited. Produced by The University of Wisconsin School of Pharmacy, Madison, WI; and Haymarket Medical, New York, NY.

Nutescu EA. Guest Editor: Strategies for Cost-Effective Prevention and Treatment of Venous Thromboembolism. (ACPE Accredited) *Am J Health-Syst Pharm* 2004;61(23 Suppl 7):S1-S24.

Bauman JL. Nutescu EA. Guest Editor: Updates in the Development of Oral Direct Thrombin Inhibitors. *Pharmacotherapy* 2004;24(10 Pt 2):165S-199S.

Nutescu EA. Guest Editor: Current Concepts in Thrombosis Management: Focus on Factor Xa Inhibition. *Pharmacotherapy* 2004;24(7 Pt 2):61S-99S.

Jacobs LG, Nutescu EA, Smith DA. Thrombosis management: long-term care perspective. Proceedings of a live symposium held at the Annual Meeting of the American Medical Directors Association; 2003 March 6-9; Orlando, Florida. Published as a supplement to *Annals of Long-Term Care and Clinical Geriatrics*.

Bussey HB, Bauer KA, Haines ST, Nutescu EA, Racine E. Continued advances in the prevention of venous thromboembolism: current trends in antithrombotic therapy. Proceedings of a live symposium held at the Annual Meeting of the American College of Clinical Pharmacy; 2001 October 24; Tampa, Florida. ACPE Accredited.

Nutescu E (Chair), Hanson P, Kaul S, Lee A, Racine E. Low-molecular-weight heparins: a fresh look at antithrombotic practices. Proceedings and CD-Rom of a live symposium held at the American Society of Health-Systems Pharmacists, Midyear Clinical Meeting; 2001 December 3; New Orleans, Louisiana. ACPE Accredited.

Hawkins D, Kondo ML, Nutescu E, Wittkowsky AK. Direct thrombin inhibitors: current use and future roles. Proceedings of a live symposium held at the Annual Meeting of the American College of Clinical Pharmacy; 2000 November 5-8; Los Angeles, California. ACPE Accredited.

INVITED PRESENTATIONS (Selected):

International:

“The Anticoagulation Clinic of the Future.” Invited Speaker: 11th Dawn AC Anticoagulation Therapy Management Software User Group Meeting. Milnthorpe, England, November 24, 2003.

“Comparison of Point of Care Fingertick Testing with Routine Laboratory International Normalized Ratio (INR) Measurement: The US Experience.” The 8th Meeting Of The Balkan Clinical Laboratory Federation – Invited Lecture. Sinaia, Romania, September 21, 2000.

“Pharmacotherapy Lecture Series: Ischemic Heart Disease, Acute Myocardial Infarction, Acute Coronary Syndromes, Antithrombotics and Thrombolytics.” Visiting Lecturer in Khon Kaen, Thailand, July 10-14, 2000.

National:

“Fondaparinux: Clinical Data Overview.” and “Pharmacoeconomic Considerations of Antithrombotic Choice.” Invited Faculty: Glaxo Smith Kline – National Speaker Training for Argatroban and Fondaparinux. Dallas, TX, March 8-9, 2005.

“Prophylaxis of Venous Thrombosis in Surgical Patients.” Invited Speaker: American College of Surgeons Puerto Rico Chapter – 55th Annual Meeting. CME. San Juan, Puerto Rico, February 17, 2005.

“Meeting the Challenges in the Prevention and Treatment of DVT and PE.” Invited Speaker: American Society of Health-Systems Pharmacists - 39th Midyear Clinical Meeting. ACPE. Orlando, FL, December 6, 2004.

“New Directions in Thrombosis Management: Adopting Optimal Treatment Strategies.” Program Chair and Invited Speaker: American Society of Health-Systems Pharmacists - 39th Midyear Clinical Meeting. ACPE. Orlando, FL, December 5, 2004.

“New Directions in Anticoagulation Therapy for Atrial Fibrillation.” Invited Speaker: Pri-Med Mid East Regional Continuing Medical Education Conference. Sponsored by the University of Wisconsin Medical School and ProCom International. Boston, MA, October 28, 2004.

“Anticoagulation in Special Populations: Managing the Hypercoagulable Patient.” Invited Speaker: American College of Clinical Pharmacy – Annual Meeting. (ACPE) Dallas, TX, October 26, 2004.

“Oral Anticoagulation: Preparing for Change.” Invited Speaker: National Conference for Geriatric Nurse Practitioners (NCGNP) – 23rd Annual Convention. Phoenix, AZ, September 30, 2004.

“Strategies for Cost-Effective Prevention and Treatment of Venous Thromboembolism.” Clinical Program Chair and Invited Speaker: American Society of Health-Systems Pharmacists - Summer Meeting. ACPE. Las Vegas, NV, June 19, 2004.

“Managing Venous Thromboembolism: An Update on Current Clinical Approaches.” Invited Speaker: Part of Advances in the Management of Venous Thromboembolism: New Pharmacologic Considerations, a Satellite Symposium presented during the Pharmacotherapy Preparatory Course – Updates in Therapeutics of the American College of Clinical Pharmacy. ACPE. Austin, TX, June 6, 2004.

“Oral Anticoagulation in the Future: What’s in the Pipeline ?” Invited Speaker: American Society of Consultant Pharmacists – 26th Midyear Conference. ACPE. Scottsdale, AZ, May 13, 2004.

“NSAIDs, Anticoagulation, DVT Prophylaxis and the Colorectal Surgeon.” Invited Speaker: Annual Meeting of the American Society of Colon & Rectal Surgeons. CME. Dallas, TX, May 9, 2004.

“Therapeutic Advances in Anticoagulation: Stroke Prevention in Atrial Fibrillation.” Invited Speaker: Annual Meeting of the American College of Physicians/American Society of Internal Medicine. CME. New Orleans, LA, April 21, 2004.

“Oral Anticoagulation: Preparing for Change.” Invited Speaker: American Medical Directors Association Annual Meeting. CME. Phoenix, AZ, March 5, 2004.

“Current and Emerging Treatment Options for Venous Thrombosis.” Invited Speaker: American Society of Health-Systems Pharmacists - 38th Midyear Clinical Meeting. ACPE. New Orleans, LA, December 11, 2003.

“Challenges in Anticoagulation Therapy: A Case Based Approach.” Program Chair and Invited Speaker: American Society of Health-Systems Pharmacists - 38th Midyear Clinical Meeting. ACPE. New Orleans, LA, December 9, 2003.

“Low Molecular Weight Heparins 2004: Incorporating Emerging Data into Clinical Practice.” Program Chair and Invited Speaker: American Society of Health-Systems Pharmacists - 38th Midyear Clinical Meeting. ACPE. New Orleans, LA, December 7, 2003.

“The Changing Landscape of Dyslipidemia: Emerging Approaches to Achieving Lower Lipoprotein Targets.” Program Chair and Invited Speaker. Academy of Managed Care Pharmacists – Annual Meeting. ACPE. Montreal, Canada, October 16, 2003.

“Controversies in Anticoagulation: Treating DVT in the Cancer Patient.” Washington State Pharmacy Association and Anticoagulation Network. ACPE. Seattle, WA, September 25, 2003.

“Guidelines for VTE Prophylaxis in Hospitalized Medical Patients.” American Society of Health-System Pharmacists. National ACPE Series. Seattle, WA, September 24, 2003.

“The Future of Anticoagulation Clinics” Part of a Pro-Con Debate at the 7th National Anticoagulation Forum Meeting. CME/ACPE. San Francisco, CA, May 10, 2003.

“Current and Emerging Trends in Antithrombotic Therapy for Venous Thromboembolism.” Westchester & Rockland Society of Pharmacists. ACPE. Westchester, NY, March 19, 2003.

“Thrombosis Management: Long-Term Care Perspective” Annual Meeting of the American Medical Directors Association. CME. Orlando, FL, March 6, 2003.

“Antithrombotic Therapy In High Risk Populations.” Washington State Pharmacy Association and Anticoagulation Network. ACPE. Seattle, WA, January 30, 2003.

“New Approaches to Oral Anticoagulation: The Evolving Role of Pharmacists.” American Society of Health-System Pharmacists - 37th Midyear Clinical Meeting. Atlanta, GA, December 9, 2002.

“Improving Outcomes in Patients at Risk of VTE.” American Society of Health-System Pharmacists - 37th Midyear Clinical Meeting. Atlanta, GA, December 9, 2002.

“Coagulation and Cancer: Current and Expanded Use of Low Molecular Weight Heparins.” American Society of Health-System Pharmacists - 37th Midyear Clinical Meeting. Atlanta, GA, December 9, 2002.

“Selective Antithrombotic Therapy: Targeting Factor Xa to Reduce Thrombotic Risk Following Major Hip and Knee Surgery.” ACPE - National Teleconference Series. June 17, 2002 – October 28, 2002.

“Pharmacokinetics of Low Molecular Weight Heparins in Special Patient Populations.” Part of “Frontiers in Anticoagulant, Antiplatelet, and Thrombolytic Therapies” International Symposium. CME Program. Washington, DC, November 9, 2002.

“Anticoagulation in Long-Term Care: The State of the Art.” American Society of Consultant Pharmacists 24th Midyear Conference. Las Vegas, NV, May 15, 2002.

“Updates in Antithrombotic Therapy.” McKesson Medication Management National Educational Seminar Series. ACPE. Colorado Springs, CO, April 22, 2002.

“New Advances In Hemostasis Management.” (Chair) American College of Clinical Pharmacy – Spring Practice and Research Forum. UIC Continuing Education Program. Savannah, GA, April 7, 2002.

“Updates in the Management of Venous Thromboembolism.” (Chair) American Society of Health-System Pharmacists - 36th Midyear Clinical Meeting. UIC Continuing Education Program. New Orleans, LA, December 2, 2001.

“Low Molecular Weight Heparins: A Fresh Look at Antithrombotic Practices.” (Chair & Presenter) American Society of Health-System Pharmacists - 36th Midyear Clinical Meeting. UIC Continuing Education Program. New Orleans, LA, December 3, 2001.

“Current Trends In Antithrombotic Therapy: A Focus On Pentasacharides.” Part of “Continued Advances in the Prevention of Venous Thromboembolism.” American College of Clinical Pharmacy - Annual Meeting. Continuing Education Program. Tampa, FL, October 24, 2001.

“New Strategies in the Treatment of Venous Thromboembolism: A Focus on Cancer Patients.” The University of Arizona Health Sciences Regional CME & ACPE Program. Tempe, AZ, October 13, 2001.

“Practical Issues in the Management of Anticoagulation in Special Patient Populations.” Part of “Emerging Trends in Antithrombotic Therapy.” (Program Chair & Presenter) American Society of Health-System Pharmacists - 35th Midyear Clinical Meeting. UIC Continuing Education Program. Las Vegas, NV, December 3, 2000.

“Direct Thrombin Inhibitors: Current Use and Future Roles.” American College of Clinical Pharmacy – Annual Meeting. Continuing Education Program. Los Angeles, CA, November 7, 2000.

“How to Bill for Clinical Pharmacy Services: Reimbursement Nuances in a Hospital Outpatient Facility.” Presented at: American Society of Health-System Pharmacists - Midyear Clinical Meeting. Las Vegas, NV, December 2, 2000; American College of Clinical Pharmacy - Spring Practice and Research Forum. Monterey, CA, April 1, 2000; American College of Clinical Pharmacy - Annual Meeting. Kansas City, MS, October 23, 1999.

“Perspectives On Narrow Therapeutic Index Drugs: The Case Of Warfarin.” American Society of Health-System Pharmacists - 34th Midyear Clinical Meeting. Continuing Education Program. Orlando, FL, December 7, 1999.

“Antithrombotic Therapy Updates: A Focus On Peri-Procedures Bridging With Low Molecular Weight Heparins.” American Society of Health-System Pharmacists – 34th Midyear Clinical Meeting. Continuing Education Program. Orlando, FL, December 6, 1999.

“Preventing and Treating Thrombosis - Update on the Use of Low-Molecular-Weight Heparins: Considerations in Special Patient Populations.” American Society of Health-System Pharmacists – 34th Midyear Clinical Meeting. Continuing Education Program. Orlando, FL, December 5, 1999.

Regional/Local:

“Controversies in Anticoagulation: Management of the High Risk Pregnant Patient.” Department of Obstetrics and Gynecology – Physician Education Conference Series. The University of Illinois at Chicago Medical Center, Chicago, IL, April 8, 2005.

“Emerging Trends in the Management of Venous Thrombosis.” Invited Speaker: Florida Society of Health-System Pharmacists – Continuing Education Regional Meeting. ACPE Accredited. Fort Lauderdale, FL, April 6, 2005.

“New Advances in the Prophylaxis and Treatment of Venous Thrombosis.” Invited Speaker: St. Joseph Hospital, Internal Medicine and Pharmacy Grand Rounds. Chicago, IL, March 31, 2005.

“New Anticoagulants.” And “Anticoagulants in Special Populations.” Invited Speaker: Part of the 6th Annual Antithrombotic Therapy Symposium. A Regional Continuing Education (CME/ACPE) Symposium sponsored by the Detroit Medical Center, and Henry Ford Hospital. Dearborn, MI, March 21, 2005.

“The American College of Chest Physicians 7th Consensus Guidelines on Antithrombotic and Thrombolytic Therapy: A Detailed Review.” Invited Speaker: Pharmacy Grand Rounds. Valley Medical Center, Renton, WA; Overlake Hospital, Bellevue, WA. January 27-28, 2005.

“Emerging Options in the Treatment of Venous Thrombosis: A Focus on Novel Anticoagulants.” Invited Speaker: The New York City Society of Health-System Pharmacists, Regional Continuing (ACPE) Education Program. New York, NY, November 18, 2004.

“Current and Future Prophylactic Approaches to the Complex Medical Patient.” Invited Faculty: VTE Prophylaxis TRACK Advisory Group Meeting, sponsored by Elsevier Science Continuing Education. Chicago, IL, October 30, 2004.

“Prevention and Treatment of VTE: A Focus on the 2004 ACCP Consensus Guidelines.” Invited Speaker: The Baylor Rehabilitation Institute – Grand Rounds. Dallas, TX, October 26, 2005.

“New Horizons in Antithrombotic Therapy: Moving Beyond Traditional Agents.” Course Director and Invited Speaker: The University of Illinois at Chicago – Regional Continuing Education Program. Oak Brook, IL, October 9, 2004.

“Low Molecular Weight Heparins: Use in Special Patient Populations.” Invited Speaker: Resurrection Health Care System – Pharmacy Grand Rounds. ACPE Accredited. Des Plaines, IL, September 21, 2004.

“Anticoagulation in Special Patient Populations: Focus on Renal Impairment and Obesity.” Invited Speaker: Medicine Grand Rounds. Methodist Hospital, Dallas Medical Center. Dallas, TX, September 17, 2004.

“Anticoagulation Therapy: What’s New on the Horizon.” Invited Speaker: Part of the 52nd Annual Pharmacy Practice Seminar, a Regional Continuing Education (ACPE) Symposium sponsored by the University of Texas at Austin, College of Pharmacy. Austin, TX, September 12, 2004.

“Ximelagatran: The End of Antithrombotic Clinics ?” Invited Speaker: The Southeastern College of Anticoagulation Providers Annual Meeting in conjunction with the University of Tennessee Health Science Center Colleges of Medicine, Nursing, and Pharmacy. Nashville, TN, September 11, 2004.

“Anticoagulation Therapy in Special Patient Populations.” Invited Speaker: Part of the 1st Annual Mid-Atlantic Antithrombotic Therapy Symposium, a Regional Continuing Education (ACPE) Symposium sponsored by the University of Maryland, School of Pharmacy. Baltimore, MD, September 10, 2004.

“Statin Therapies for Dyslipidemia: Strategies for Optimizing Risk Reduction.” Invited Speaker: Part of the Pri-Med Pharm-Med Updates, a Regional Continuing Education (ACPE) Scientific Forum sponsored by the Postgraduate Institute for Medicine and the Pri-Med Institute. Miami, FL, September 9 2004; Detroit, MI, September 22, 2004; Houston, TX, October 1, 2004; Rosemont, IL, November 12, 2004.

“State of Affairs in Lipid Management: Dual Pathways Approach” Invited Speaker: Merck-Schering Plough. – Education Program Series. Marquette, MI, August 27, 2004.

“Advancing into a New Era of Anticoagulant Therapy.” Invited Speaker: Part of a National Continuing Education (CME/ACPE) Grand Round Series sponsored by The Johns Hopkins University School of Medicine and The University of Tennessee College of Pharmacy. Presentations given: Detroit VA Hospital, Detroit, MI, August 2, 2004; Edward Hines Jr. VA Hospital, Hines, IL, August 6, 2004; VA Medical Center, Minneapolis, MN, September 23, 2004.

“Updates in Oral Anticoagulation.” Invited Speaker: General Internal Medicine Continuing Education (CME) Conference Series. The University of Illinois at Chicago Medical Center, Chicago, IL, July 1, 2004.

“New Anticoagulation Agents: Mechanisms of Action and Clinical Implications.” Invited Speaker: Part of the Pri-Med Pharm-Med Updates, a Regional Continuing Education (ACPE) Scientific Forum sponsored by the Postgraduate Institute for Medicine and the Pri-Med Institute. Los Angeles, CA, June 16, 2004.

“Challenging the Heparin Paradigm in VTE: The Evidence-Based Role of LMWHs.” Invited Speaker: Part of a Pharmacy Continuing Education Series (ACPE) sponsored by University Pharmacotherapy Associates. Chicago, IL, June 9, 2004; Detroit, MI, September 14, 2004; Salt Lake City, UT, October 14, 2004; Schaumburg, IL, December 1, 2004.

“Updates in the Treatment of Dyslipidemia.” Invited Speaker: Rite Aid Corporation – Regional Continuing Education Series. ACPE. Sterling Heights, MI, May 23, 2004; Birmingham, AL, May 27, 2004.

“Dual Inhibition: Inhibiting Cholesterol Production and Absorption.” Invited Speaker: Merck-Schering Plough. – Education Program Series. Chicago, IL, May 25, 2004; Green Bay, WI, June 10, 2004.

“New Advances in the Pharmacologic Management of Dyslipidemia.” Invited Speaker: Part of the Dyslipidemia Forum, a Regional Continuing Education (CME/ACPE) Program hosted by the American Heart Association, Greater Midwest Affiliate. Chicago, IL, May 18, 2004.

“Strategies in the Management of Acute Coronary Syndromes.” Invited Speaker: A Local Continuing Education (CME/ACPE) Program sponsored by Advanced Health Media. Chicago, IL, March 4, 2004; Madison, WI, April 19, 2004.

“Direct Thrombin Inhibition for Anticoagulation.” Invited Speaker: Northern Michigan Society of Health System Pharmacists, Regional Continuing Education Meeting (ACPE). Gaylord, MI, April 15, 2004.

“Antithrombotic Therapy in Special Patient Populations.” Invited Speaker: Part of the 5th Annual Antithrombotic Therapy Symposium. A Regional Continuing Education (CME/ACPE) Symposium sponsored by the Detroit Medical Center, Henry Ford Hospital, and Loyola University Medical Center. Dearborn, MI, March 29, 2004.

“New Pharmacological and Non-Pharmacological Developments for the Prevention and Treatment of Thromboembolic Disease.” Invited Speaker: Part of Updates in the Prevention, Diagnosis & Management of Thromboembolic Disease. A Regional Continuing Education (CME/ACPE) Symposium sponsored by the Rockford Health System. Rockford, IL, March 10, 2004.

“The Clinical and Legal Implications of a Low Molecular Weight Heparin Therapeutic Interchange.” Regional Consultant Panel of Health System Pharmacy Directors and Clinical Coordinators. Novi, MI, June 17, 2003.

Challenging VTE Standards: Heparin, LMWHs and Evolving Agents. University Pharmacotherapy Associates ACPE Program. Bloomington, IL, June 18, 2003; Terre Haute, IN, June 19, 2003; Louisville, KY, May 22, 2003.

“Practical Anticoagulation Therapy Management of the Pregnant Patient.” Maternal and Fetal Medicine - Grand Rounds. The University of Illinois at Chicago Medical Center, Chicago, IL, June 6, 2003.

“Establishing an Anticoagulation Management Service: Operational Issues.” CME and ACPE Accredited Program. Rockford Memorial Hospital, Rockford, IL, May 21, 2003.

“Optimizing Injectable Anticoagulant Formulary Management.” University Pharmacotherapy Associates. ACPE Program. Minneapolis, MN, May 15, 2003.

“Clinical Pearls for Antithrombotic Therapy.” Henry Ford Health System, Detroit Medical Center, & Loyola University Medical Center – 4th Annual Antithrombotic Therapy Symposium – Continuing Education CME/ACPE Program. Dearborn, MI, March 5, 2003.

“Bridging Patients With Low Molecular Weight Heparin.” Postgraduate Institute for Medicine – Regional CME Conference. Louisville, KY, February 26, 2003.

“Updates in Treatment of VTE: Focus on Pulmonary Embolism.” Grand Rounds, CME Program. Saint Mary’s Hospital, Chicago, IL, January 21, 2003.

“New Therapeutic Options for Managing Venous Thromboembolism.” Iowa Pharmacy Association – Annual Educational Expo. Des Moines, IA, January 17, 2003.

“Controversies in Antithrombotic Therapy: Focus On Special Patient Populations.” Grand Rounds, CME Program. Saint Francis Hospital, Evanston, IL, October 18, 2002.

“Controversies In Thromboembolism Management.” Henry Ford Health System & Detroit Medical Center - 3rd Annual Antithrombotic Therapy Symposium – Continuing Education CME/ACPE Program. Dearborn, MI, March 6, 2002.

“Best Practices In Anticoagulation Management.” Illinois Council of Health Systems Pharmacists Annual Meeting. Oak Brook, IL, September, 15, 2001.

“Direct Thrombin Inhibitors: Anticoagulants of the Future” University of Illinois at Chicago Regional ACPE Program. Oak Brook, IL, May 30, 2001.

“Low Molecular Weight Heparin Management Service.” Henry Ford Health System & Detroit Medical Center – 2nd Annual Antithrombotic Therapy Symposium – Continuing Education CME/ACPE Program. Dearborn, MI, March 7, 2001.

“Emerging Trends In The Use Of Low Molecular Weight Heparins.” South Suburban Pharmacists Association – Continuing Education Program. Glenwood, IL, January 10, 2001.

“Advances in Antithrombotic Therapy: DVT Prophylaxis and Justification of LMWHs In The Long Term Care Setting.” Jacobs Health Care – Omni Care, Pharmacy and Nursing Advisory Boards. Des Plaines, IL, September 5, 2000.

“Proper Anticoagulation Management of Patients Maintained On Long Term Warfarin Therapy Requiring Dental Surgery.” Department of Oral Surgery – Invited Lecture. The University of Illinois at Chicago College of Dentistry, Chicago, IL, August 14, 2000.

“Prevention of Venous Thromboembolism in Orthopedic Surgery: Focus On Low Molecular Weight Heparins.” Department of Orthopedic Surgery – Grand Rounds. The University of Illinois at Chicago Medical Center, Chicago, IL, May 31, 2000.

“New Advances In Antithrombotic Therapy: Focus On Low Molecular Weight Heparins.” Internal Medicine Grand Rounds. Continuing Medical Education Program. Saint Elizabeth Hospital, Chicago, IL, May 16, 2000.

“Preventing and Treating Thrombosis: The Role of Low Molecular Weight Heparins.” Department of Physical Medicine and Rehabilitation. The University of Illinois at Chicago Medical Center, Chicago, IL, May 11, 2000.

“Designing and Implementing an Antithrombosis Clinic.” Illinois Council of Health System Pharmacists – Continuing Education Program. Lansing, MI, May 7-8, 2000.

“Peri-Procedure Bridging With Low Molecular Weight Heparins: Practical Considerations and Clinical Applications.” Department of Cardiology – Grand Rounds. The University of Illinois at

Chicago Medical Center, Chicago, IL, April 10, 2000.; Department of Internal Medicine – Grand Rounds. The University of Illinois at Chicago Medical Center, Chicago, IL, February 15, 2000.

“Management of Venous Thromboembolism: A Focus On New Antithrombotic Agents.” MedPoint Communications. Regional CME/ACPE Continuing Education Program. EauClaire, WI, October 4, 2000.

“Controversial Issues In The Use Of Low Molecular Weight Heparins.” Anticoagulation Specialty Meeting - Invited Lecture. CME and ACPE accredited. Parkview Memorial Hospital & Health System, Fort Wayne, IN, September, 14, 2000.

“Low Molecular Weight Heparins: A View On The Current Market Place, Formulary And Pharmacoeconomic Considerations.” Columbia HCA, National Pharmacy Advisory Board Meeting (Pharmacy Directors and P&T Members) – Invited Lecture. Mineapolis, MN, August 29, 2000.

“Antithrombotic Therapy: Update on Low Molecular Weight Heparins in Clinical Practice.” Cleveland Society of Health-System Pharmacists. Continuing Education Program. Cleveland, OH, January 26, 2000.

“Designing and Implementing an Anticoagulation Clinic. Live and Internet-Based Continuing Education Certificate Programs.” Topics presented: Clinic Development and Justification; Practical Issues in Warfarin Dosing; Antithrombotic Agents: Pharmacology and Therapeutics; Regulatory Issues: CLIA’88; Low Molecular Weight Heparins: Class Review and Outpatient Use, Cost Justification and Compensation for Services. The University of Illinois at Chicago, College of Pharmacy, Chicago, IL, programs each offered yearly 1999-present.

“Antithrombotic Therapy: New Advances in the Use of Low Molecular Weight Heparins.” The University of Illinois at Chicago – Regional Continuing Education Program. Oak Brook, IL, November 17, 1999.

“Evolving Concepts with Low Molecular Weight Heparins: A Medicine Use Policy Approach.” South Florida Society of Health System Pharmacists. Continuing Education Program. Miami, FL, August 26, 1999.

“Helping Patients Help Themselves: Home Diagnostic and Monitoring Devices.” Pharmacy Society of Wisconsin Annual Meeting. Continuing Education Program. La Crosse, WI, August 13, 1999.

“Anticoagulation Focus Session: Practical Issues In Dosing Oral Anticoagulants and Outpatient Management of DVT.” Michigan Society of Health System Pharmacists Annual Conference. Continuing Education Program. Grand Rapids, MI, May 5, 1999.

“Antithrombotic Therapy Updates: Management Of Patients On Oral Anticoagulants & Establishing An Outpatient DVT Treatment Program.” Munson Medical Center’s Regional Program on Antithrombotic Therapy. Continuing Education Program. Traverse City, MI, April 15, 1999.

GRANTS AND CONTRACTS:

Research:

Humma LM, Nutescu EA (co-I), Helgason CM, Shord S. “Cyclooxygenase-1 Genotype and Aspirin Response in Stroke.” Grant funded by American Health Assistance Foundation: National Heart Foundation. 4/04 – 3/06; \$50,000.

Schumock G, Nutescu EA (co-I), Walton S. “Economic Model for Use of Low-Molecular-Weight Heparins in Community Hospitals.” Mercy Resource Management Inc. 6/03-6/04; \$15,000.

Pickard S, Nutescu EA (co-I), Schumock G, Wittkowsky AK, Ansell J. “Implications of Direct Thrombin Inhibitors for Anticoagulation Clinics.” Grant funded by Astra Zeneca. 1/03-12/04; \$34,700.

Nutescu EA (PI). “Guidelines for Antithrombotic Therapy in Special Patient Populations.” Grant funded by Aventis Pharmaceuticals. 10/02-9/03; \$12,000.

Nutescu E (PI), Helgason C. “DVT Free.” Grant funded by Genecom, LLC. 10/01-3/02; \$15,000.

Nutescu E. (PI) “Low Molecular Weight Heparin Management Services.” Grant funded by Aventis Pharmaceuticals. 6/01-5/02; \$31,250.

Nutescu EA. (PI) “Antithrombosis Treatment Education.” Grant funded by Bristol-Myers Squibb Pharmaceuticals. 10/01-6/02; \$30,000.

Schumock G, Nutescu E (co-I), Lewis R, Walton S. “Evaluation of Appropriate Use of LMWHs in Integrated Delivery Networks.” Grant funded by Aventis Pharmaceuticals. 1/00-12/02; \$92,000.

Schumock G, Nutescu E (co-I), Lewis R, Walton S. “Analysis of Factors that Influence Prescribing of LMWHs in Acute Care Hospitals.” Grant funded by Dupont Pharmaceutical Company. 1/01-12/02; \$100,000.

Nutescu E (PI), Shapiro N. “Feasibility of INR - Patient Self Testing In A University Based Antithrombosis Clinic.” The University of Illinois at Chicago Antithrombosis Clinic. Funding: Roche. 2001; \$10,000.

Engle J, Nutescu E (co-I), Joseph J. “Internet Based Anticoagulation Certificate Program: Designing and Implementing an Anticoagulation Clinic.” The University of Illinois College of Pharmacy. UI Online. 2000-2001; \$36,000.

Nutescu EA. (PI), Antithrombotic Resource Manual. Funding: DuPont. 2000; \$10,000.

Nutescu EA (PI), Helgason CM. “LMWH Use in Patients on Long-Term Warfarin Therapy, Requiring Minor Outpatient Surgical Procedures.” Grant funded by Pharmacia & Upjohn. 2/99-12/00; \$10,000.

Education/Training:

Antithrombosis Management Preceptorship. Chicago, IL. May 2005. Course Director; Astra Zeneca \$7,500; Sanofi-Aventis \$10,500.

New Horizons in Antithrombotic Therapy: Moving Beyond Traditional Agents. Oak Brook, IL, October 9, 2004. Course Director; Astra-Zeneca \$110,000.

Antithrombosis Therapy Management: Designing, Implementing, and Retooling Your Service for the Future. Internet Based Certificate Program. Chicago, IL. April-May, 2004. Course Director; Aventis \$5,000; Bristol Myers Squibb \$25,000.

Antithrombosis Management Preceptorship. Chicago, IL. Fall 2003 – Spring/Fall 2004. Course Director; Astra Zeneca \$15,000; Sanofi-Synthelabo \$ 5,000.

Antithrombotic Therapy Updates and Training Program. Chicago, IL. Fall 2003. Program Chair and Content Coordinator; Aventis \$35,000.

Challenges in Antithrombotic Therapy: A Case Based Approach. New Orleans, LA. December, 2003, in conjunction with the ASHP Midyear Clinical Meeting. Program Chair and Content Coordinator; Pharmion \$75,000.

New Advances in Hemostasis Management. Savannah, GA. April 2002, in conjunction with the ACCP Spring Practice and Research Forum. Program Chair and Content Coordinator; NovoNordisk \$65,000.

New Advances in the Management of Dyslipidemia. Oak Brook, IL. October 2002. Program Chair; Astra Zeneca \$85,000.

Contemporary Antithrombotic Therapy. San Diego, CA. April 2001. Program Chair. DuPont \$125,000.

Low-Molecular Weight Heparins In Venous Thromboembolism: Bridging The Evidence To Clinical Practice. Chicago, IL, Los Angeles, CA, Miami, FL, Dallas, TX, New Orleans, LA. May – December 2001. Program Chair and Content Coordinator; DuPont \$500,000.

Antithrombosis Management Certificate Program. Internet Based Certificate Program. Chicago, IL. Spring 2001. Content Director; DuPont \$25,000.

Low Molecular Weight Heparins In Special Patient Populations. Chicago, IL. May 2001. Program Chair; Aventis \$55,000.

Low Molecular Weight Heparins: A Fresh Look at Antithrombotic Practices. New Orleans, LA. December, 2001 in conjunction with the ASHP Midyear Clinical Meeting. Program Chair; Pharmacia \$125,000.

Direct Thrombin Inhibitors: Anticoagulants Of The Future. Oak Brook, IL. May 2001. Program Chair; Astra Zeneca \$90,000.

Low-Molecular Weight Heparins In Special Populations. Las Vegas, NV. December, 2000 in conjunction with the ASHP Midyear Clinical Meeting. Program Chair; DuPont \$100,000.

Oral Direct Direct Thrombin Inhibitors. Las Vegas, NV. December 2000, in conjunction with the ASHP Midyear Clinical Meeting. Program Chair; Astra Zeneca \$95,000.

Antithrombosis Management Certificate Program. Internet & Live Certificate Programs. Chicago, IL. Spring 2000. Content Director; DuPont \$30,000; Barr \$10,000.

Perspectives On Narrow Therapeutic Index Drugs: The Case Of Warfarin. Orlando, FL. December 1999, in conjunction with the ASHP Midyear Clinical Meeting. Program Chair; DuPont \$25,000.

Antithrombotic Therapy Updates: A Focus On “Peri-Procedure Bridging” With Low Molecular Weight Heparins. Orlando, FL. December 1999, in conjunction with the ASHP Midyear Clinical Meeting. Program Chair; Pharmacia & Upjohn \$40,000; Rhone-Poulenc Rorer \$10,000.

New Advances In Antithrombotic Therapy. Las Vegas, NV. December 1998, in conjunction with the ASHP Midyear Clinical Meeting. Program Chair; Pharmacia & Upjohn \$45,000.

HONORS AND AWARDS:

Bristol Myers Squibb Antithrombosis Management Service Excellence Award, November, 2002.

The Illinois Pharmacy Foundation Literature Award, September 1998.

For the paper “Multidisciplinary approach to improving allergy documentation.”

Tri - State Leadership Pharmacy, 1997.

Selected as one of 10 Illinois participants

INVITED REVIEWER:

American Journal of Health System Pharmacists

Annals of Pharmacotherapy

British Journal of Clinical Pharmacology

Drugs

Expert Opinion in Pharmacotherapy

Expert Opinion on Investigational Drugs

Expert Opinion on Drug Safety

Journal of Applied Therapeutics

Journal of General Internal Medicine

Journal of Pharmacy Teaching

Pharmacotherapy

Reviews on Recent Clinical Trials
KeePosted
Thrombosis and Haemostasis

EDITORIAL BOARDS:

Reviews on Recent Clinical Trials. Peer-Reviewed Journal published by Bentham Science Publishers. Editorial Board Member, 2005 – present.

ClotCare. OnLine Resource for Health-Care Professionals. Editorial Board Member, 2004 – present.

PROFESSIONAL SERVICE:

Service to the University:

Scholarship and Awards Committee, Member. The University of Illinois at Chicago, College of Pharmacy. 2004 – Present.

JCAHO Tracer Teams, Member and Mock Surveyor. The University of Illinois at Chicago, Hospital and Ambulatory Care Center. 2004 – 2005.

Clinical Values Task Force. The University of Illinois at Chicago, Ambulatory Care Pharmacy Services. 2002 - 2003.

Laboratory Committee on Point of Care Testing. The University of Illinois at Chicago, Medical Center. 2002 - 2004.

Research and Scholarly Activities Committee. The University of Illinois at Chicago, Ambulatory Care Pharmacy Services. 1998 - 2000.

College Admissions Interviewer, Prospective Doctor of Pharmacy Students. The University of Illinois at Chicago, College of Pharmacy. 1997 – Present.

Ambulatory Care Residency Admissions Committee. The University of Illinois at Chicago, College of Pharmacy. 1997 – 1999.

Reimbursement for Clinical Services Committee. The University of Illinois at Chicago, Ambulatory Care Pharmacy Services. 1996 - 2002.

Policy and Procedure Committee. The University of Illinois at Chicago, Ambulatory Care Pharmacy Services. 1996 – 2000.

Ambulatory Care Section Committee. The University of Illinois at Chicago, College of Pharmacy. 1996 – 2000.

Student Advisor for Doctor of Pharmacy Students. The University of Illinois at Chicago, College of Pharmacy. 1996 – Present.

Pharmacy Liaison, Surgery Clinic. The University of Illinois at Chicago, Medical Center. 1996 – 1998.

Quality Assurance and Quality Improvement Committee. The University of Illinois at Chicago, College of Pharmacy. 1995 - 1996.

Congestive Heart Failure Multidisciplinary Task Force. The University of Illinois Medical Center. 1995 - 1996.

Service to the Profession:

American College of Clinical Pharmacy. Ambulatory Care PRN - Frontiers Fund Committee. Member. 2004-2005.

American Society of Health System Pharmacy. Section of Clinical Specialists and Scientists – Committee on Nominations. Member. 2004 – 2005.

The National Quality Forum and the Joint Commission on the Accreditation of Healthcare Organizations. National Consensus Standards for the Prevention and Care of Deep Vein Thrombosis. Member, Steering Committee. (Nominated by the American Society of Health System Pharmacists) 2005 – present.

National Consumers League. SOS Rx Coalition: Oral Anticoagulant National Advisory Board. Member. (Representing the American College of Clinical Pharmacy). 2004 – present.

American College of Clinical Pharmacy. Spring Forum (2006) Program Committee. Member. 2004-2005.

American Society of Health System Pharmacy. Anticoagulation Network. Network Facilitator. 2000 - 2001.

American College of Clinical Pharmacy. Task Force on Compensation. 1998 - 2001.
Northern Illinois Society of Health System Pharmacy. President. 2000 – 2001.

Northern Illinois Society of Health System Pharmacy. Delegate to the House. Fall 1998, Fall 1999, Fall 2000

American College of Clinical Pharmacy. Ambulatory Care PRN. Education Committee. 1998 - 1999.

American Pharmaceutical Association. Credentialing Advisory Panel on Anticoagulation. 1998.

Illinois College of Clinical Pharmacy. Professional Relations Committee. 1996 - 1997.

Illinois Council of Health System Pharmacy. KeePosted. Assistant Editor. 1998 - 2001.

Illinois Council of Health System Pharmacy. KeePosted. Editorial Advisor. 1995 - 1998.

Illinois Council of Health System Pharmacy. Education Committee. 1997 - present.

Illinois Council of Health System Pharmacy. Illinois Pharmacy Congress Planning Committee. 1997 - 1999.

Illinois Council of Health System Pharmacy. Reimbursement Committee, 1996.

Chicago Area Anticoagulation Forum, Planning Committee. 1996 - present.

PROFESSIONAL AFFILIATIONS:

International Society of Thrombosis and Haemostasis, 2001-present

American Heart Association, Stroke Council, 1999 – present

American Association of Colleges of Pharmacy, 1997 - present

Anticoagulation Forum, 1997 - present.

Chicago Area Anticoagulation Forum, 1996 - present.

American College of Clinical Pharmacy, 1994 - present.

Illinois College of Clinical Pharmacy, 1994 - present.

Illinois Council of Health System Pharmacists, 1994 - present.

Northern Illinois Society of Health System Pharmacists, 1994 - present.

American Society of Health System Pharmacists, 1993 - present.

OTHER PROFESSIONAL APPOINTMENTS OR CONSULTANCIES:

HELIX – a National Thrombogenic Network of Anticoagulation Clinics coordinated by the Anticoagulation Forum, Duke University Thrombosis Center and Boston University Medical Center. Member, Executive Committee, 2005 – present.

PICAT - Annual Pharmacy Invitational Conference on Antithrombotic Therapy coordinated by the University of Wisconsin Extension Services in Pharmacy in conjunction with the American Society of Health System Pharmacists Midyear Clinical Meeting. Member, Planning Committee, 2005 - present.

TRACK -Thrombosis Resource for the Advancement of Clinical Knowledge, sponsored by Elsevier Continuing Medical Education. Member, VTE Prophylaxis Advisory Group, 2004.

Advancing into a New Era of Anticoagulant Therapy. A National Continuing Education (CME/ACPE) Grand Round Series sponsored by The Johns Hopkins University School of Medicine and The University of Tennessee College of Pharmacy. Member, Planning Committee, 2004.

Boehringer Ingelheim Pharmaceuticals. Member, Dabigatran DVT Treatment and Prevention Advisory Panel, 2005.

EXCHANGE Study (A multicenter, randomized, open label, prospective comparison of ximelagatran to low molecular weight heparin as bridging during invasive procedures in patients

receiving chronic anticoagulation with vitamin K antagonists). Member, Steering Committee, 2004.

Farallon Medical, Inc. Consultant, 2004 – present.

NABOR - National Anticoagulation Benchmark and Outcomes Report: Hospital Study of Anticoagulation Practices. Member, Steering Committee, 2004.

Princeton Media Associates, LLC. Managed Care Consultant: Anticoagulation Digest. Series Consultant Editor, 2004.

Aventis Pharmaceuticals. Faculty Advisor, Special Patient Populations: National Consultant Panel, 2004; Member, Pregnancy and Thrombosis Consensus Working Group, 2003-2004.

University Pharmacotherapy Associates. Member, Expert Consensus Panel: Unfractionated Heparin Contemporary Issues, 2003.

Industry: Aventis Pharmaceuticals Inc., AstraZeneca, DuPont Pharma, Glaxo Smith Kline, Merck, Pharmion Corporation, Pharmacia, Pfizer, Sanofi-Synthelabo, Sanofi-Aventis, Schering-Plough. Consultant; Member, various Thrombosis/Cardiovascular/Anticoagulation Advisory Boards. 1997 – present. (each over different time periods).